COVID-19 in chronic lymphocytic leukaemia


  • Heather Mason
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

According to a case study reported in the Lancet Haematology, clinical and biochemical data of COVID-19 might be partly masked by coexisting chronic lymphocytic leukaemia or compromised immunity.

A 39-year-old male with chronic lymphocytic leukaemia presented to hospital with a four-day history of fever, sore throat, productive cough and dyspnoea. Blood parameters were; a white blood cell count of 91·85 × 109 cells/L, lymphocytes 96%, haemoglobin 85 g/L, platelet count of 79 × 109 cells/L. A chest CT scan showed bilateral ground-glass opacities indicative of COVID-19.

He was treated with oral chlorambucil, nebulised α-interferon, intravenous human immunoglobulin, and intravenous methylprednisolone, and received non-invasive ventilation therapy until dyspnoea subsided (day 8). A follow-up chest CT showed substantial improvement. A repeat COVID-19 test remained positive.

Without the complete travel history, COVID-19 infection was not initially suspected, because his whole blood cell and lymphocyte counts were high. This was due to his chronic lymphocytic leukaemia masking a potential infection. This case is interesting because the estimated incubation period for COVID-19 infection is thought to be no more than 14 days. However, a retrospective review of the patient's condition suggested an incubation period of about 25 days.

Individuals with compromised immune status might be subjected to a longer incubation period.